December 3, 2015
|Avg. Volume (3 mo.)||884,704|
Income Statement Snapshot
|Net Loss (LFY)||(A$1.9M)|
Balance Sheet Snapshot
PharmAust Limited ("PAA,” "PharmAust,” or the "Company”) specializes in the relaunch of existing marketed products for oncology applications making the whole development, regulatory, and commercialization process much faster. Its pipeline includes human and veterinary proprietary medicines to treat cancer. PharmAust has two key strategic alliances with major pharmaceutical companies and products already in clinical trials. These products target substantial multi-billion dollar markets. In addition, PharmAust's wholly-owned subsidiary, Epichem Pty Ltd, generates sales of around $1.7M per annum from contract sales of synthetic drugs to the pharmaceutical industry. Epichem also facilitates the generation of new IP by synthesizing similar drug formulations for projects within the Company.
PharmAust's current market cap of A$6.2 million is significantly lower than the median market cap of A$47 million for similar companies in Phase I/II trials treating various types of cancer. PAA's lead product MPL successfully completed Phase I trials in humans and Phase II trials are expected to begin in 1Q16.
MPL has shown the ability to suppress p70s6k in both human and animal studies. Successful cancer drugs Rapamycin and Everolimus, with estimated multibillion dollar markets, have also been shown to inhibit p70s6k. MPL has the potential to improve upon these types of drugs, as its low toxicity enables higher possible doses and preclinical studies have shown a reversal in drug resistance, which is critical as many patients become resistant to chemotherapy over time.
- PPL-1 Monepantel (MPL) showed suppression of p70s6k in a successful Phase I trial
- Patients who have a poor response to chemotherapy have high p70s6k levelss
- Overexpression of p70s6k in breast cancer patients correlates with a poor prognosis
- P70s6k has been shown to lead to malignant transformation of cancers
- MPL’s low toxicity avoids the dosing limitations and toxicity of other approved cancer drugs
- Preclinical studies show reversal of drug resistance
- MPL can potentially be used as a combination therapy
- Revenue generated by Rapamycin (Novartis) and Everolimus (Pfizer) are in the billions
- Rapamycin and Everolimus both inhibit p70s6k and interfere with mTOR (mTOR is the mechanistic target of rapamycin)
- Novartis Animal Health has registered MPL to treat parasitic diseases in animals (“Zolvix”)
- In a clinical study, MPL showed the suppression of p70s6k in dogs
- Top 5 pharma company has an option on veterinary cancer applications
- Epichem sales forecast to reach $10 million by 2020
- Epichem also serves as support for the MPL program